

Tissue Regenix Group PLC

03:41 09 Mar 2016

Tissue Regenix PLC granted US clearance for hernia implant

Regenerative medtech Tissue Regenix (LON:TRX) has been granted US regulatory clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue.

It is the first time an implant using Tissue's cell washing technology has been approved by the US Food and Drug Administration.

The clearance clears SurgiPure XD for a commercial launch in the US later this year.

Antony Odell, Tissue Regenix's chief executive, said he was delighted with this first clearance for a dCELL application.

"The US is a key market for us and we have proven that we can successfully commercialise product here already with DermaPure [a skin graft for open wounds].

SurgiPure XD will be used alongside dCELL to repair hernias or body wall defects by bolstering areas where soft tissue has been weakened.

The hernia market is worth US\$2-3bn with the US alone worth US\$1bn. Biologic treatments account for around US\$300mln.

"Tissue Regenix dCELL applications are quickly gaining clinical validation and demand on an international scale, through both the Wound Care and Cardiac sectors, a testament to the strength of our dCELL technology platform," said Odell.

Price: 1.025

Market Cap: £12.01 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: TRX

Listing: AIM

52 week High Low
8.4 0.45

Sector: Pharma & Biotech

Website: www.tissuregenix.com

Company Synopsis:

TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL®, addressing soft tissue needs, and BioRinse™, providing inductive bone allografts. We are helping to transform the treatment of patients in three key areas: BioSurgery, Orthopaedics & Dental and Cardiac.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to
Twenty Five Thousand dollars (\$25,000).